The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia

Therapeutic Advances in Hematology - Tập 7 Số 3 - Trang 142-156 - 2016
Jonathan Benjamin1, Anthony S. Stein2
1Amgen Inc., Global Development, Oncology, Thousand Oaks, CA, USA
2Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, 1500 East Duarte Road, Duarte, CA 91010-3000, USA

Tóm tắt

Adults with relapsed/refractory B-acute lymphoblastic leukemia (ALL) have a complete remission (CR) rate of 20–45% and median overall survival of 3–9 months, depending on the duration of the first remission and number of lines of salvage therapy. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative option for adult patients with relapsed/refractory ALL, and achievement of CR is a crucial step before alloHSCT. Blinatumomab is a bispecific T-cell engager (BiTE®) antibody construct with dual specificity for CD19 and CD3, simultaneously binding CD3-positive cytotoxic T cells and CD19-positive B cells, resulting in T-cell-mediated serial lysis of normal and malignant B cells. It recently gained accelerated approval by the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory Philadelphia chromosome-negative ALL, based on a large phase II trial of 189 adults with relapsed/refractory B-ALL, which showed a CR/CRh (CR with partial hematologic recovery) of 43% after two cycles of treatment. Toxicities include cytokine-release syndrome (CRS) and neurologic events (encephalopathy, aphasia, and seizure). CRS can be alleviated by step-up dosing and dexamethasone, without affecting the cytotoxic effect of blinatumomab. The cause of neurologic toxicity is unclear but is also observed with other T-cell therapies and may relate to variable expression of CD19 within the brain. This review encompasses the preclinical rationale of using the BITE® class of compounds (blinatumomab being the only one that is FDA approved), with clinical data using blinatumomab in the relapsed/refractory setting (pediatrics and adults), the minimal residual disease setting (adults), as well as Philadelphia chromosome-positive ALL. The review also examines the main adverse events: their prevention, recognition, and management; possible mechanisms of resistance; causes of relapse. It also summarizes future trials evaluating the drug earlier in the treatment course to improve activity.

Từ khóa


Tài liệu tham khảo

American Cancer Society (2014) Cancer Facts and Figures. Atlanta, GA: American Cancer Society Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index (accessed 25 August 2015).

Baeuerle P., 2009, Curr Opin Mol Ther, 11, 22

10.1158/0008-5472.CAN-09-0547

10.1126/science.1158545

10.1007/s00262-007-0298-z

10.1182/blood-2005-07-2708

10.1097/00007890-199004000-00009

10.1016/j.leukres.2008.08.025

10.1126/scitranslmed.3008226

10.1002/ijc.10557

10.1182/blood.V124.21.2291.2291

10.1182/blood-2006-05-018192

Goebeler M., 2013, Hematol Oncol, 31, 302

10.1182/blood.V124.21.379.379

10.1182/blood.V126.23.680.680

10.1182/blood-2011-09-377713

10.1182/blood-2011-12-399287

10.1182/blood.V124.21.3703.3703

10.1007/s00262-003-0496-2

10.1056/NEJMoa1215134

10.1016/j.imbio.2008.11.014

10.1002/ijc.20908

10.1189/jlb.1212621

10.1038/nature01076

10.1200/jco.2015.33.15_suppl.7043

10.1182/blood-2012-01-400515

10.1182/blood-2011-10-384388

Kranick S., 2014, Neurology, 82, S52.006, 10.1212/WNL.82.10_supplement.S52.006

10.1053/j.seminhematol.2006.01.007

Ledbetter J., 1986, J Immunol, 136, 3945, 10.4049/jimmunol.136.11.3945

10.1182/blood-2014-05-552729

10.1200/JCO.2002.07.116

10.1182/blood.V95.6.2098

Martinelli G., 2015, Blood, 126, 679, 10.1182/blood.V126.23.679.679

10.1016/j.pharmthera.2012.07.013

10.1097/00007691-199512000-00012

10.1016/j.molimm.2005.03.007

10.3324/haematol.2009.014274

10.1158/1078-0432.CCR-15-0612

10.3109/10428194.2011.559668

10.1007/s40265-015-0356-3

10.1007/s00262-005-0082-x

10.1182/blood.V88.4.1188.bloodjournal8841188

10.1038/sj.leu.2404824

10.1182/blood-2013-02-485623

10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O

10.1016/S1470-2045(14)71170-2

10.1182/blood-2012-07-441030

10.1200/JCO.2014.56.3247

10.1200/JCO.2010.32.7270

10.1200/jco.2015.33.15_suppl.7051

10.1038/nature13954

10.1016/0090-1229(87)90156-5

10.1038/nrd4597

10.1182/blood.V124.21.2292.2292

10.1186/2162-3619-1-36

Weiss A., 1991, Semin Immunol, 3, 313

10.1101/cshperspect.a005140

10.1016/j.molimm.2015.02.033

Thông tin
Thông tin xuất bản

Therapeutic Advances in Hematology

Tập 7 Số 3

142-156

Thông tin tác giả